BI 891065

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Carcinoma, Non-Small-Cell LungNeoplasmNeoplasm MetastasisNeoplasms

Phase 1

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

TerminatedNCT03166631

Boehringer IngelheimCarcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

Start: 2017-09-08End: 2020-10-28Updated: 2024-11-19

A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours)

CompletedNCT04138823

Boehringer IngelheimNeoplasm

Start: 2019-11-26End: 2023-05-17Updated: 2024-10-09

Related Papers

The Second Mitochondria-Derived Activator of Caspases Mimetic BI 891065 in Patients With Advanced Solid Tumors: Results From Two Phase I Studies.

2025-12-011 citations

Synergistic effects of Smac mimetic APG-1387 with anti-PD-1 antibody are attributed to increased CD3 + NK1.1 + cell recruitment secondary to induction of cytokines from tumor cells

Cancer Cell International2024-05-243 citations

Abstract 1951: SMAC mimetic and BET inhibitor - a promising combination for solid cancer treatment

Cancer Research2021-07-011 citations